Valuation: Portage Biotech Inc

Market Cap 7.49M 6.65M 6.22M 5.67M 10.67M 721M 10.81M 75.22M 29.12M 367M 28.11M 27.5M 1.18B P/E 2027 *
-0.35x
P/E 2028 * -0.57x
Enterprise Value 7.49M 6.65M 6.22M 5.67M 10.67M 721M 10.81M 75.22M 29.12M 367M 28.11M 27.5M 1.18B EV / Sales 2027 *
0.41x
EV / Sales 2028 * 0.33x
Free-Float
-
Yield 2027 *
-
Yield 2028 * -
Manager TitleAgeSince
Chief Executive Officer 38 03/08/2025
Director of Finance/CFO 39 24/10/2025
President 56 16/07/2026
Director TitleAgeSince
Director/Board Member 38 03/08/2025
Chairman 56 03/09/2025
Director/Board Member 69 25/09/2025
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.88%-4.81%+28.47%+35.03% 44.25B
+0.93%+3.72%+352.03%+692.13% 43.99B
-1.76%+0.06%+7.47%+101.79% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.69%-9.62%-25.41%+333.01% 24.93B
Average +0.19%+1.97%+54.67%+160.41% 44.09B
Weighted average by Cap. +0.36%+1.83%+58.94%+151.66%

Financials

2027 *2028 *
Net sales 18.18M 16.15M 15.1M 13.76M 25.91M 1.75B 26.26M 183M 70.72M 891M 68.26M 66.78M 2.86B 22.8M 20.25M 18.94M 17.26M 32.49M 2.2B 32.94M 229M 88.69M 1.12B 85.6M 83.75M 3.59B
Net income -19.9M -17.68M -16.53M -15.06M -28.36M -1.92B -28.75M -200M -77.41M -976M -74.71M -73.09M -3.13B -19.5M -17.32M -16.2M -14.76M -27.79M -1.88B -28.17M -196M -75.85M -956M -73.21M -71.63M -3.07B
Net Debt - -
Logo Portage Biotech Inc
Portage Biotech Inc. develops pharmaceutical and biotech products through to clinical proof of concept focusing on unmet clinical needs. After proof of concept, the Company will look to sell or license the products to various pharmaceutical companies for further development through to commercialization. The Company's research and development work is primarily carried out through approximately two subsidiaries, including Portage Pharmaceuticals Ltd (PPL) and Biohaven Pharmaceutical Holding Company Limited (Biohaven). The Company also holds interests in Sentien Biotechnologies Inc., a regenerative medicine company. PPL focuses on discovering and developing cell permeable peptide (CPP) therapies to normalize gene expression, restore function and improve medical outcomes. Biohaven is engaged in the identification and development of glutamatergic agents for treatment-resistant neuropsychiatric disorders. Its product pipeline includes PPL-003, BHV-0223 and BHV-4157.
Employees
-